We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Individual researchers and university leaders need to make the case for science to their elected representatives and to the public at large.

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

For years, my son grew up as a perfectly healthy kid, despite being diagnosed with CF-related metabolic syndrome. But when he suddenly developed pancreatitis, I had a hunch it was actually related to ...

It has been six months since the N.W.T. government introduced its revamped extended health benefits (EHB) program, which ...

From today, the updated indication for TRIKAFTA is as follows: TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in ...

You've probably heard a lot about something called the Pharmaceutical Benefits Scheme — or the PBS — this week. Here are some ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...